EN DE
Watch Telesis Bio Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Telesis Bio Inc. (TBIO) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Telesis Bio Inc. stock $0.03, price $0.01, upside +200.0%, quality 37 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TB Telesis Bio Inc. logo Thin data Oct 30, 2026

Telesis Bio Inc.

TBIO · US
Cheap, value-trap risk

The stock costs 67% less than our calculation considers fair.

Fair value $0.0300 · Strongly undervalued (67%)
Low debt
Even on cautious assumptions the value is 173% above the price ($0.0273).
Mixed Growth (revenue 5y +80.9 %/yr in USD)
Quality 37/100
Loss-making · -173.5% net margin (FY2023)
Negative free cash flow
Trails peers (1/7)
Narrow moat 5/100
Thin data
⚠ Thinly traded
Watch Telesis Bio Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$311.40 $0.0001 Fair Value $0.0300 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range $0.0001 – $311.40 · fair‑value band $0.0273 – $0.0352 · the $0.0100 price screens below the $0.0300 fair value. As of Oct 30, 2026.

Follow Telesis Bio in your weekly email

Every Wednesday you see whether Telesis Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.

Show moreShow less

The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.

It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines.

It has license agreement with Regeneron Pharmaceuticals, Inc. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022.

Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Stock analysis

Telesis Bio Inc. (TBIO) currently trades at $0.0100, while our model-based Fair Value estimate is $0.0300, implying the stock looks roughly 66.7% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.

Scenario range: $0.0273 (bear) to $0.0352 (bull), the price of $0.0100 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Telesis Bio Inc. reported revenue of $27.5M in FY2023 versus $4.8M in FY2019, a compound +54.7%/yr. Reported net income was −$47.7M in FY2023.

Key figures

Market cap $68.5K Micro · EPS (TTM) $−22.99 · Return on equity −179% · Return on assets (EBIT) −46.5% · Operating margin −328% · Revenue (TTM) $17.0M · Revenue growth (YoY) −61.8% · Free cash flow −$36.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 91% below its 52-week high and 9,900% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 200%, TBIO screens cheaper than that median.

Fair Value models

Bear $0.0273 Fair Value $0.0300 Bull $0.0352
Price $0.0100 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.0274 $0.0367 $0.0548 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0274 $0.0367 $0.0548 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 36
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 33
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,250.7% (2018) → −169.2% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

Watch TBIO, get fair value alerts →

Compare Telesis Bio Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −4.9% · Above median
Profitability
Return on assets −67.8% · Bottom 25%
Net margin (12 months) −173.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −61.8% · Bottom 25%
Balance sheet
Debt / equity 0.18× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 10
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 16
HEALTH (low debt)91 · sector 98
DIVIDEND (yield)0 · sector 36

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $311.75 $342.93 +10% vs TBIO
Boston Scientific Corporation BSX $42.43 $46.67 +10% vs TBIO
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥175.30 ¥192.83 +10% vs TBIO
DexCom, Inc DXCM $79.93 $87.92 +10% vs TBIO
GE HealthCare Technologies Inc GEHC $75.82 $69.99 −8% vs TBIO
Edwards Lifesciences Corporation EW $94.44 $82.04 −13% vs TBIO
Siemens Healthineers AG SHL €42.89 €35.21 −18% vs TBIO
Abbott Laboratories, ABT $103.10 $75.28 −27% vs TBIO
Medtronic plc MDT $97.11 $65.61 −32% vs TBIO
Koninklijke Philips N.V PHIA €23.78 €15.23 −36% vs TBIO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Telesis Bio Inc. · Fair Value
$0.0300 +67%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Telesis Bio Inc. Fair Value". https://www.fairvalue-calculator.com/stock/TBIO

Frequently asked questions

Is Telesis Bio Inc. (TBIO) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.0300 versus a price of $0.0100, about +200% upside (undervalued).
What is the fair value of TBIO?
Our model-based fair value for Telesis Bio Inc. is $0.0300 (as of Oct 30, 2026), built from audited fundamentals. The current price: $0.0100.
What is the quality score of TBIO?
Telesis Bio Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Telesis Bio Inc. (TBIO)?
Our model-based price target is the fair value of $0.0300 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.0273, optimistic scenario $0.0352. It is a calculation from audited fundamentals, not an analyst target.
What is the Telesis Bio Inc. stock forecast for 2026?
Our models put fair value at $0.0300, about +200% upside versus a price of $0.0100 (undervalued). Cautious scenario $0.0273, optimistic scenario $0.0352. The calculation is refreshed regularly with new filings.
What is the revenue of Telesis Bio Inc. (TBIO)?
Telesis Bio Inc. reported trailing-twelve-month revenue of about $17.0M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Telesis Bio Inc. (TBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Telesis Bio Inc. it is $0.0300 per share (as of Oct 30, 2026), against a price of $0.0100. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Telesis Bio Inc. stock overvalued or undervalued in 2026?
As of Oct 30, 2026, TBIO trades below its calculated fair value: price $0.0100, fair value $0.0300, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TBIO?
No. The price is what the market pays today ($0.0100); the fair value is what the company's own numbers justify ($0.0300). For Telesis Bio Inc. the two are $0.0200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Telesis Bio Inc. worth?
The market values Telesis Bio Inc. at about $68.5K (market capitalisation, as of Oct 30, 2026). Per share that is $0.0100; our models calculate a fair value of $0.0300 per share.
What do the bullish and bearish scenarios say about TBIO?
Our models span a range for Telesis Bio Inc.: cautious scenario $0.0273, base $0.0300, optimistic $0.0352 per share (as of Oct 30, 2026, price $0.0100). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Telesis Bio Inc. (TBIO)?
Balance-sheet figures for Telesis Bio Inc. (as of Oct 30, 2026): return on equity −179.0%, debt of 0.18 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is TBIO from its 52-week high?
Telesis Bio Inc. trades at $0.0100, about 91% below its 52-week high of $0.1100 and 9,900% above the low of $0.0001 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.
Which stocks are comparable to Telesis Bio Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Telesis Bio Inc. stock attractive at the current price?
The data as of Oct 30, 2026: price $0.0100, calculated fair value $0.0300 (+200%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TBIO calculated?
We run Telesis Bio Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Telesis Bio Inc. currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Telesis Bio Inc. (TBIO)?
The closing price on Oct 30, 2026 was $0.0100. Our model-based fair value is $0.0300, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Telesis Bio Inc. right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.0273). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Telesis Bio Inc.

How large is the market capitalisation of Telesis Bio Inc. (TBIO)?
The market capitalisation of Telesis Bio Inc. is $68.5K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Telesis Bio Inc. (TBIO)?
Earnings per share at Telesis Bio Inc. are $−22.99. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Telesis Bio Inc. (TBIO)?
The return on equity (ROE) of Telesis Bio Inc. is −179% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Telesis Bio Inc. (TBIO)?
On an EBIT basis the return on assets of Telesis Bio Inc. is −46.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Telesis Bio Inc. (TBIO)?
The operating margin of Telesis Bio Inc. is −328% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Telesis Bio Inc. (TBIO)?
Revenue at Telesis Bio Inc. is growing −61.8% versus a year earlier (3y avg +61.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Telesis Bio Inc. (TBIO) generate?
The free cash flow of Telesis Bio Inc. is −$36.6M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Telesis Bio Inc. (TBIO) carry?
The net debt of Telesis Bio Inc. is $32.8M (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Telesis Bio Inc. in the live analysis

One click puts Telesis Bio Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.